H-Index
34
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
call: +1.631.629.4327
Mon-Fri 10 am - 2 pm EST

Logo



eISSN: 2329-0358

Get your full text copy in PDF

Lung Transplantation and Systemic Sclerosis

Ivan Rosas, John V Conte, Stephen C Yang, Sean Gaine, Marvin Borja, Frederic M Wigley, Barbara White, Jonathan B Orens

Ann Transplant 2000; 5(3): 38-43

ID: 497538


We performed lung transplantation in nine patients with Scleroderma related lung disease. Patient characteristics included: 7 (78%) females, 6 (67%) with limited and 3 (33%) with diffuse Scleroderma. Pulmonary fibrosis was present in 7 (78%) and pulmonary hypertension in 4 (44%). All patients were carefully screned by the Johns Hopkins and University of Maryland Scleroderma Center and only referred for transplantation '{'(hen concomitant renal insufficiency (creatinine clearance :$50 ml/min): aspiration, and skin brakdown were excluded. When compared to a similar group of transplant patients with nonscleroderma lung disease (primary pulmonary fibrosis), there was no significant difference in post-transplant survival at four years (76.2:t0.15% vs. 69.2%:t0.12%), mean annual incidence rate for acute rejection (0.14:t0.14 vs. OA7:t0.13) and infection (viral 0.17:t0.17 vs. 0.29:t0.11) (bacterial 0.17:t0.17 vs. 1.4:tOA) (fungal 0.99:t0.69 vs. 0.36:t0.16) or serum creatinine (1.55 :to.34 mg/dl vs. 1.15 :to.09 mg/dl). We conclude that lung transplantation is viable option for carefuly selected patients with scleroderma related lung disease.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree